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Imiquimod: Clinical Effects
Hadley and co-workers analyzed 
data from five randomized, dou-
ble-blind, controlled trials lasting 
12–16 weeks and involving 1,293 
patients to assess the cost and ben-
efits of the immune response modi-
fier imiquimod in treating actinic 
keratosis (AK). Complete clearance 
of AK occurred in 50% of patients 
treated with imiquimod compared 
with 5% of those treated with con-
trol. The proportion of patients with adverse events was substantially higher with 
imiquimod than with control. Imiquimod 5% cream was found to be effective in 
preventing the development of squamous-cell carcinoma. Future research might 
elucidate optimal dosing to minimize adverse events and evaluate long-term recur-
rence. See page 1251 
A Locus for Inversa Acne
Inversa acne (hidradenitis suppurativa) is usu-
ally localized in non-facial regions and is 
worldwide in distribution. The genetic basis of 
acne inversa is unknown. Gao and colleagues 
performed a genome-wide scan in a four-gen-
eration Chinese family to map the chromosome 
location of the responsible gene. They identi-
fied a locus at chromosome 1p21.1–1q25.3 
and observed the range of markers. This first 
locus for acne inversa will be a starting point 
for understanding the molecular mechanisms 
of this disease. See page 1302
Desmoglein 4 and Beaded Hair
Localized autosomal recessive hypotri-
chosis (LAH), a recently defined disorder 
characterized by fragile, short, sparse 
hairs on the scalp, trunk, and extremities, 
has been traced to mutations in the des-
moglein 4 (DSG4) gene. In three siblings 
of Iraqi and Iranian origin with LAH, con-
genital scalp erosions and monilethrix-
like hairs are now also attributed to LAH. 
Schaffer and colleagues’ observations 
of novel heterozygous DSG4 mutations 
broaden the phenotypic and genotypic 
spectrum of LAH. Increasing clinical 
awareness of LAH in the differential diag-
nosis of autosomal forms of hypotrichosis will allow identification of more cases and 
help to better define the range of pathogenic DSG4 mutations. See page 1286
Paying the Toll
Imiquimod’s antitumoral and 
antiviral efficacy is mediated 
through the Toll-like receptor 
7 (TLR7) and TLR8 signaling 
cascade, but Schön et al. 
have demonstrated that 
imiquimod has broader 
and more complex 
biological activity than 
previously recognized. 
The authors propose 
imiquimod generates 
inflammation via two 
complementary mechanisms: 
it induces the production of 
proinflammatory mediators 
via the known TLR7- and 
TLR8-dependent signaling 
pathways, and antagonizes 
an important suppressive 
feedback mechanism through 
A2A adenosine receptor.  See 
page 1338 
Suppressing Keloids
Modulation of vascular 
endothelial growth factor 
(VEGF) production may treat 
keloids. Wu et al. treated 
primary keloid fibroblast (KF) 
cultures with dexamethasone, 
VEGF-A antibody, and a VEGF 
receptor-2 antagonist  VEGF 
protein.  It appears that 
dexamethasone suppresses 
KF proliferation and 
downregulates endogenous 
VEGF expression. See page 
1264 
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